Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIxico Regulatory News (IXI)

Share Price Information for Ixico (IXI)

Share Price is delayed by 15 minutes
Get Live Data
8.65    0.00 (0.00%)
Bid:
8.30
Ask:
9.00
Spread: 0.70 (8.434%)
Market Cap: £18.86m
IXI Live PriceLast checked at - London Stock Exchange

Intraday Ixico Share Chart

Director/PDMR Shareholding

14 Sep 2007 08:55

Phytopharm PLC14 September 2007 NOTIFICATION OF TRANSACTIONS OF DIRECTORS, PERSONS DISCHARGING MANAGERIALRESPONSIBILITY OR CONNECTED PERSONS This form is intended for use by an issuer to make a RIS notification requiredby DR 3.1.4R(1. (1) An issuer making a notification in respect of a transaction relating toshares or debentures of the issuer should complete boxes 1 to 16, 23 and 24. (2) An issuer making a notification in respect of a derivative relating tothe shares of the issuer should complete boxes 1 to 4, 6, 8, 13, 14, 16, 23 and24. (3) An issuer making a notification in respect of options granted to adirector/person discharging managerial responsibilities should complete boxes 1to 3 and 17 to 24. (4) An issuer making a notification in respect of a financial instrumentrelating to the shares of the issuer (other than a debenture) should completeboxes 1 to 4, 6, 8, 9, 11, 13, 14, 16, 23 and 24. Please complete all relevant boxes in block capital letters. 1. Name of the issuer 2. State whether the notification relates to (i) a transaction notified in accordance with DR 3.1.4R(1)(a); or PHYTOPHARM PLC (ii) DR 3.1.4R(1)(b) a disclosure made in accordance with section 324 (as extended by section 328) of the Companies Act 1985; or (iii) both (i) and (ii) NOTIFICATION RELATES TO (iii) 3. Name of person discharging 4. State whether notification managerial responsibilities/ relates to a person connected director with a person discharging managerial responsibilities/ director named in 3 and identify the connected person DR DARYL REES AS 3 ABOVE 5. Indicate whether the notification 6. Description of shares (including is in respect of a holding of the class), debentures or derivatives person referred to in 3 or 4 or in or financial instruments relating respect of a non-beneficial to shares interest AS 3 ABOVE OPTIONS OVER ORDINARY SHARES OF 1 PENCE EACH 7. Name of registered shareholder(s) 8. State the nature of the and, if more than one, the number transaction of shares held by each of them GRANT OF AN SAYE SHARE OPTION UNDER THE PHYTOPHARM SHARESAVE PLAN 2007 9. Number of shares, debentures or 10. Percentage of issued class financial instruments relating to acquired (treasury shares of that shares acquired class should not be taken into account when calculating percentage) 11. Number of shares, debentures or 12. Percentage of issued class financial instruments relating to disposed (treasury shares of that shares disposed class should not be taken into account when calculating percentage) 13. Price per share or value of 14. Date and place of transaction transaction 15. Total holding following 16. Date issuer informed of notification and total percentage transaction holding following notification (treasury shares of that class should not be taken into account when calculating percentage) If a person discharging managerial responsibilities has been granted options bythe issuer complete the following boxes 17. Date of grant 18. Period during which or date on which it can be exercised 12 SEPTEMBER 2007 1 OCTOBER 2010 TO 31 MARCH 2011 19. Total amount paid (if any) for grant 20. Description of shares or of the option debentures involved (class and number) NIL 19,585 PHYTOHARM PLC ORDINARY 1 PENCE SHARES 21. Exercise price (if fixed at the time 22. Total number of shares or of grant) or indication that price is debentures over which options to be fixed at the time of exercise held following notification EXERCISE PRICE FORTY EIGHT AND ONE 1,278,559 QUARTER PENCE PER SHARE 23. Any additional information 24. Name of contact and telephone number for queries ZOE MCGOWAN 01480 437697 Name and signature of duly authorised officer of issuer responsible for makingnotification------------------------------------------------___ZOE MCGOWAN_________________________________________________________ Date of notification _14 SEPTEMBER 2007____________________________________ ------------------------------------------------ This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
25th May 20217:00 amRNSHalf yearly report to 31 March 2021
20th May 20217:00 amRNSPhase II Alzheimer’s disease contract award
19th May 20217:00 amRNSContract win for new neuroinflammatory disorder
11th May 20217:00 amRNSNotice of results
28th Apr 20217:00 amRNSContract win for new stroke study
26th Apr 20217:00 amRNSTrading update
19th Apr 20218:21 amRNSHolding(s) in Company
12th Apr 20214:00 pmRNSHolding(s) in Company
12th Apr 20217:00 amRNSInvestment in Ixico plc
1st Apr 20217:00 amRNSHolding(s) in Company
25th Mar 20219:14 amRNSPDMR Transaction
24th Mar 20219:05 amRNSSecond Price Monitoring Extn
24th Mar 20219:00 amRNSPrice Monitoring Extension
23rd Mar 20214:40 pmRNSSecond Price Monitoring Extn
23rd Mar 20214:35 pmRNSPrice Monitoring Extension
23rd Mar 20213:05 pmRNSHuntington’s disease Phase III contract updates
15th Mar 20214:41 pmRNSSecond Price Monitoring Extn
15th Mar 20214:35 pmRNSPrice Monitoring Extension
15th Mar 20212:06 pmRNSSecond Price Monitoring Extn
15th Mar 20212:00 pmRNSPrice Monitoring Extension
15th Mar 202111:06 amRNSSecond Price Monitoring Extn
15th Mar 202111:01 amRNSPrice Monitoring Extension
15th Mar 20217:00 amRNSCollaboration with Microsoft
10th Mar 20217:00 amRNSIXICO chosen for new Phase II AD study
2nd Mar 20217:00 amRNSIXICO selected by Cyclerion for a new AD study
1st Mar 20215:25 pmRNSExercise of Options; PDMR Dealing
1st Mar 20217:00 amRNSConference attendance and presentations
29th Jan 202110:19 amRNSPDMR Dealing
21st Jan 202111:05 amRNSResult of AGM
7th Jan 20217:00 amRNSIssue of Equity
24th Dec 20207:00 amRNSIXICO secures new contract for £3.4 million
14th Dec 202011:54 amRNSHolding(s) in Company
8th Dec 20207:00 amRNSIXICO contract with new large global pharma
3rd Dec 20202:06 pmRNSSecond Price Monitoring Extn
3rd Dec 20202:01 pmRNSPrice Monitoring Extension
2nd Dec 20207:00 amRNSFinancial Results for the year ended 30 Sept 2020
27th Nov 20207:00 amRNSIXICO announces £1.9 million new study award
9th Nov 20207:00 amRNSNotice of Results
3rd Nov 20207:00 amRNSAdditional Alzheimer’s disease contracts
22nd Oct 20207:00 amRNSFurther Huntington’s disease contracts
19th Oct 20207:00 amRNSIXICO to Present at SCA & ARCA Global Conference
19th Oct 20207:00 amRNSTrading Update for year ended 30 September 2020
16th Oct 20207:00 amRNSIXICO and NYU Langone Health sign agreement
30th Sep 20202:05 pmRNSSecond Price Monitoring Extn
30th Sep 20202:00 pmRNSPrice Monitoring Extension
29th Sep 20207:00 amRNS>£2m contract extension win - Huntington’s disease
24th Sep 20207:00 amRNSCollaboration with TRACK-FA NeuroimagingConsortium
21st Sep 20207:00 amRNSIXICO selected to support Alzheimer’s trial
11th Sep 202010:36 amRNSHolding(s) in Company
26th Aug 202011:55 amRNSInvestor presentation

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.